Original ArticlesNo Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive PatientsWu, Na PhD∗,†; Liu, Liangjie MD∗,†; Ren, Decheng PhD∗,†; Yuan, Fan PhD∗,†; Bi, Yan PhD∗,†; Guo, Zhenming PhD∗,†; Hou, Binyin MD∗,†; Ji, Lei PhD∗,†; Han, Ke PhD∗,†; Feng, Mofan PhD∗,†; Su, Kai PhD∗,†; Yu, Tao PhD∗,†; Li, Xingwang PhD∗,†; Yang, Fengping MD∗,†; Sun, Xueli PhD‡; Dong, Zaiquan PhD‡; Yu, Shunying PhD†; Yi, Zhenghui PhD†; Xu, Yifeng PhD†; He, Lin PhD∗,†; Wu, Shaochang PhD§; Zhao, Longyou PhD§; Changqun, Cai PhD∥; Shi, Yi PhD∗,†; He, Guang PhD∗,†Author Information From the ∗Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, Shanghai †Shanghai Key Laboratory of Psychotic Disorders, Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai ‡Psychological Center, West China Hospital, Sichuan University, Sichuan §Lishui No. 2 People's Hospital, Zhejiang ∥Wuhu No. 4 People's Hospital, Anhui, China. Address correspondence and reprint requests to Yi Shi, PhD, or Guang He, PhD, Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, 1954 Huashan Rd, Shanghai 200030, China; E-mail: [email protected] (G.H.); [email protected] (Y.S.) Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. This work was supported by the National Key Research and Development Program (2016YFC0906400), Shanghai Science and Technology Innovation Project (20JC1418600), Natural Science Foundation of Shanghai (20ZR1427200), the National Nature Science Foundation of China (82071262, 81671326, and 8142106), the Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), Shanghai Municipal Science and Technology Major Project (2017SHZDZX01), the Shanghai Leading Academic Discipline Project (B205), and the Interdisciplinary Program of Shanghai Jiao Tong University (YG2019ZDA30). This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study. Clinical Neuropharmacology: 3/4 2021 - Volume 44 - Issue 2 - p 53-56 doi: 10.1097/WNF.0000000000000436 Buy Metrics Abstract Objective Major depressive disorder (MDD) is a heterogeneous psychiatric disorder and considered to be one of the most common mental diseases worldwide. The antidepressant venlafaxine, as a serotonin noradrenaline reuptake inhibitor, is applied to MDD relief. Solute carrier family 6 member 4 (SLC6A4) has been reported to promote the reuptake of serotonin and to be closely correlated to depression. The present study examined whether rs6354 and rs1487971 in SLC6A4 are associated with remission after venlafaxine treatment in MDD patients. Methods This study consisted of 195 Han Chinese patients with MDD, who accepted a 6-week treatment with venlafaxine. Two SLC6A4 single-nucleotide polymorphisms (SNPs) were selected from database of SNP and genotyped by matrix-assisted laser desorption/ionization time of flight mass spectrometer in MassARRAY Analyzer 4 platforms. The 17-item Hamilton Depression Scale was used to access the severity of major depression. Allele and genotype frequencies between patients in remission and nonremission were calculated with online software SHEsis. Results No significant differences in allele or genotype frequencies were observed in rs6354 and rs1487971. There were no significant associations between 2 SNPs and venlafaxine treatment outcome. Conclusions It suggested that rs6354 or rs1487971 within SLC6A4 appears not to be involved in the venlafaxine treatment outcome in Han Chinese patients with MDD. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.